刊名:Journal of Pharmaceutical and Biomedical Analysis
出版年:2017
出版时间:5 February 2017
年:2017
卷:134
期:Complete
页码:71-76
全文大小:797 K
卷排序:134
文摘
The compound 83b1 has the potential to develop as a novel anti- esophageal cancer drug for its high anti-tumor activity and low cytotoxicity. [J1] A simple, rapid and sensitive method for determination of 83b1 in rat plasma using UHPLC–MS/MS was developed and validated for the first time. The validated method was employed to study the bioavailability of 83b1 in rat by dosing with intravenous injection (1 mg/kg) and gavage (10 mg/kg).